Clinical Trial Update: High-Dose Cyclophosphamide for Steroid Refractory GVHD [Phase 2]

View source ↗

Summary

Phase 2 trial investigating high-dose cyclophosphamide for steroid-refractory graft-versus-host disease has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Graft Versus Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-09-14